Physician profile
Ngan Thi Van
NPI 1487639779
$11,211.69
in general payments reported to CMS, 2019-2025
51 companies · $857 in 2025
The $857 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $1,231 · 2021: $1,785 · 2022: $2,594 · 2023: $2,186 · 2024: $1,290 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,332.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,281.35 | 2019-2025 | Vraylar |
| Novo Nordisk INC | $1,222.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,039.77 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $848.69 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $595.88 | 2021-2025 | |
| Pfizer INC. | $465.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.06 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $377.88 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $361.99 | 2019-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $347.84 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $337.82 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $290.82 | 2019-2022 | |
| Amgen INC. | $283.76 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $268.48 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amarin Pharma, INC. | $223.82 | 2020-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ngan Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.